Cryoport, Inc. (CYRX) Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Cryoport, Inc. is a global provider of temperature-controlled supply chain solutions for the life sciences industry, with a strategic focus on the cell and gene therapy (CGT) market. The company operates two primary reportable segments: Life Sciences Services (logistics, storage, and bioservices) and Life Sciences Products (cryogenic systems and equipment). Notably, the company completed the divestiture of its CRYOPDP specialty courier business to DHL in June 2025; results from this business are classified as discontinued operations for all periods presented.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $47,798 | $41,040 |
| Gross Margin | $21,913 (45.8%) | $18,641 (45.4%) |
| Net Loss | $(10,544) | $(11,981) |
| Net Loss Attributable to Common Stockholders | $(12,544) | $(13,981) |
| Diluted Net Loss Per Share | $(0.25) | $(0.28) |
| Adjusted EBITDA (Continuing Ops) | $(611) | $(2,819) |
| Cash and Cash Equivalents | $272,912 | $47,361 |
| Short-Term Investments | $130,722 | $160,714 |
| Convertible Senior Notes (Current Portion) | $185,390 | $185,094 |
| Operating Cash Flow | $3,735 | $(4,342) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 16.5% year-over-year to $47.8 million. Life Sciences Services revenue grew 17.6% to $26.9 million, driven by a 16.9% increase in BioLogistics Solutions and a 20.7% increase in BioStorage/BioServices. Life Sciences Products revenue rose 15.0% to $20.9 million.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 26.1% to $27.6 million. This increase was primarily due to a $5.2 million release of contingent consideration in Q1 2025 that did not recur in 2026, offset by higher wages and a decrease in stock-based compensation.
- Investment Income: Investment income surged 96.4% to $3.1 million, largely due to higher yields on the company's investment portfolio.
- Discontinued Operations: Loss from discontinued operations decreased significantly to $1.1 million in Q1 2026 compared to $5.2 million in Q1 2025, reflecting the completion of the CRYOPDP divestiture in Q2 2025. The Q1 2026 loss included a $1.1 million adjustment related to the resolution of a disposal contingency.
- Liquidity: Cash and cash equivalents increased to $272.9 million, up from $47.4 million in the prior year period, bolstered by the CRYOPDP divestiture proceeds and strong operating cash flow generation.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue incurring significant expenses and operating losses in the near term while investing in supply chain initiatives and geographic expansion. The company anticipates sufficient liquidity to meet operational requirements for at least the next 12 months, including the repayment of $186.2 million in Convertible Senior Notes due in December 2026.
- Strategic Focus: The company is leveraging its partnership with DHL to enhance capabilities in EMEA and APAC regions. It continues to support a growing number of clinical trials (766 total, with 91 in Phase 3) and commercial therapies.
- Risks: Key risks include exposure to foreign currency fluctuations (impacting revenue and intercompany balances), interest rate changes affecting investment portfolio fair value, and the potential need for additional capital if profitable operations are not sustained. The company also faces standard litigation risks and supply chain constraints.
- Repurchase Program: As of March 31, 2026, approximately $63.9 million remains available under the 2024 Repurchase Program. No repurchases were made in Q1 2026.
Investor Verification Checklist
- Verify the timing and terms of the December 2026 Convertible Senior Notes repayment, given the current portion liability of $185.4 million.
- Confirm the sustainability of investment income levels, which significantly offset operating losses in Q1 2026.
- Monitor the foreign currency exposure given that 26.9% of revenue is derived from international customers and the company holds significant foreign-denominated cash balances.
- Review the Adjusted EBITDA reconciliation to understand the impact of non-GAAP adjustments, particularly the unrealized losses on investments and stock-based compensation.
- Assess the progress of the DHL strategic partnership in driving growth in EMEA and APAC regions post-divestiture.